GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+16.63%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$640M
AUM Growth
+$640M
(+12%)
Cap. Flow
+$29.9M
Cap. Flow
% of AUM
4.68%
Top 10 Holdings %
Top 10 Hldgs %
63.77%
Holding
49
New
10
Increased
9
Reduced
7
Closed
17
Top Buys
| 1 |
Puma Biotechnology
PBYI
|
$34M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$22.3M |
| 3 |
Exelixis
EXEL
|
$19.9M |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$14.9M |
| 5 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$13.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 88.08% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Iovance Biotherapeutics
IOVA
$807M
| $56.1M | 8.34% | 3,321,173 +1,321,173 | +66% | +$22.3M |
|
|
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $51.6M | 7.66% | 1,305,887 +128,768 | +11% | +$5.09M |
|
3
Kura Oncology
KURA
$686M
| $44.6M | 6.63% | 2,380,846 +183,563 | +8% | +$3.44M |
|
4
PTC Therapeutics
PTCT
$3.92B
| $41.7M | 6.19% | 1,539,822 +454,022 | +42% | +$12.3M |
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $39.2M | 5.82% | 978,302 -143,029 | -13% | -$5.73M |
|
|
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $36.6M | 5.44% | 550,000 +139,100 | +34% | +$9.26M |
|
7
BioCryst Pharmaceuticals
BCRX
$1.74B
| $35.7M | 5.3% | 7,478,275 +2,726,392 | +57% | +$13M |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $35.6M | 5.28% | 736,631 -66,574 | -8% | -$3.22M |
|
|
9
Puma Biotechnology
PBYI
$254M
| $34M | 5.05% | +500,000 | New | +$34M |
|
10
Neurocrine Biosciences
NBIX
$13.8B
| $33.2M | 4.93% | 400,000 | – | – |
|
11
Rigel Pharmaceuticals
RIGL
$697M
| $30.4M | 4.51% | 8,579,454 +690,873 | +9% | +$2.45M |
|
|
AIMT
12
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $28.7M | 4.26% | 900,579 +327,029 | +57% | +$10.4M |
|
|
FOMX
13
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $24.5M | 3.64% | 4,781,708 | – | – |
|
|
14
Exelixis
EXEL
$10.1B
| $19.9M | 2.96% | +899,900 | New | +$19.9M |
|
|
XLRN
15
DELISTED
Acceleron Pharma Inc.
XLRN
| $18.1M | 2.68% | 462,245 +289,121 | +167% | +$11.3M |
|
16
NovoCure
NVCR
$1.38B
| $16.4M | 2.44% | 753,481 -125,805 | -14% | -$2.74M |
|
|
FPRX
17
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $14.9M | 2.21% | +868,100 | New | +$14.9M |
|
|
ACHN
18
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $13.7M | 2.04% | +3,700,000 | New | +$13.7M |
|
|
ECYT
19
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $13.6M | 2.01% | +1,491,500 | New | +$13.6M |
|
20
Savara
SVRA
$567M
| $7.93M | 1.18% | 862,179 -7,321 | -0.8% | -$67.4K |
|
|
CTIC
21
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $6.58M | 0.98% | +1,687,020 | New | +$6.58M |
|
22
Catalyst Pharmaceutical
CPRX
$2.52B
| $6.44M | 0.96% | 2,695,742 -1,121,546 | -29% | -$2.68M |
|
|
SRRA
23
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $6.44M | 0.96% | +3,111,111 | New | +$6.44M |
|
24
Vanda Pharmaceuticals
VNDA
$279M
| $5.22M | 0.78% | 309,800 -487,731 | -61% | -$8.22M |
|
|
AMRN
25
Amarin Corp
AMRN
$311M
| $3.18M | 0.47% | 1,056,825 | – | – |
|